Biotronik reports positive data from catheter ablation trial for atrial fibrillation

Medical Company Product News

Biotronik has announced new clinical trial data showing the effectiveness of catheter ablation of atrial fibrillation as a first-line treatment for people with heart failure.

Data from the CASTLE-AF study have been presented at the European Society of Cardiology Congress showing significant reductions in mortality and heart failure events with catheter ablation compared to pharmacological therapy.

“Biotronik has presented new study data showing how catheter ablation of atrial fibrillation can be an effective first-line treatment for heart failure patients.“

A 38 percent reduction in all-cause mortality and hospitalisation rates for worsening heart failure was observed when patients with atrial fibrillation received catheter ablation instead of pharmacological treatments recommended under current guidelines.

This was the world's largest randomised clinical study of catheter ablation in this patient group, with a total of 398 patients enrolled across 33 sites in Europe, Australia and the US between 2008 and 2016.

Dr Nassir Marrouche at the University of Utah said: "The results of this trial underscore the importance of catheter ablation as a mode of treatment, indicating that the procedure should be performed as early as possible and as a first-line therapy in this group of patients."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Medical Devices
Return to news

Tags